menu
    • menu
    [{"orgOrder":0,"company":"Prokarium","sponsor":"Korea Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Series B Financing","leadProduct":"Vesibax","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Prokarium \/ Korea Investment Partners","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium \/ Korea Investment Partners"},{"orgOrder":0,"company":"Prokarium","sponsor":"Prokarium","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Salmonella Typhi Immunotherapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Prokarium","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium \/ Prokarium"},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Salmonella Typhi","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Prokarium \/ Not Applicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"RNA-based Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"2","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Prokarium","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Prokarium","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Prokarium \/ Ginkgo Bioworks","highestDevelopmentStatusID":"5","companyTruncated":"Prokarium \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"ZH9","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Not Applicable"},{"orgOrder":0,"company":"Prokarium","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"ZH9","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Prokarium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Prokarium \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Prokarium \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Prokarium

    Menu

    Prokarium

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZH9

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prokarium Doses First Patient in PARADIGM-1 Trial for Non-Muscle Invasive Bladder Cancer

                            Details : ZH9 is a live attenuated S. enterica serovar Typhi ZH9, a differentiated novel microbial immunotherapy. It is being evaluated in phase 1 clinical trials for non-muscle invasive bladder cancer.

                            Brand Name : ZH9

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            February 07, 2024

                            Lead Product(s) : ZH9

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ZH9

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

                            Details : ZH9 is being developed as an intravesical monotherapy treatment for the prevention of recurrences in bladder cancer. The PARADIGM-1 study is expected to enroll in H1 2024 across multiple centers in the United States.

                            Brand Name : ZH9

                            Molecule Type : Undisclosed

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : ZH9

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Ginkgo Bioworks

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Plat...

                            Details : Proceeds will support clinical development of the Company’s lead oncology candidate in non-muscle invasive bladder cancer and accelerate platform discovery.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Ginkgo Bioworks

                            Deal Size : $30.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Ginkgo Bioworks

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immun...

                            Details : Bactofection, the process of transferring genetic material into a mammalian cell via a bacterium, is an alternative gene delivery system that could deliver therapeutic agents to a patient in RNA-based therapy.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 09, 2023

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Ginkgo Bioworks

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salmonella Typhi

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Prokarium Strengthens Patent Position Through Notice of Allowance of US Patent for Immunotherapy Prime in Comb...

                            Details : Salmonella Typhi delivered orally with an adoptive T cell therapy or an allogeneic or autologous CAR T-cell therapy to increase the therapeutic efficacy of the cell therapy.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : Salmonella Typhi

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Salmonella Typhi Immunotherapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Lausanne University Hospital

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Prokarium Exercises Option for an Exclusive Worldwide License for the Use of Salmonella Immunotherapy in the T...

                            Details : Department of Urology at CHUV has generated a robust preclinical data package demonstrating that Prokarium’s proprietary Salmonella bacteria generates quantitatively and qualitatively superior immune responses with different kinetics compared to the st...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 02, 2022

                            Lead Product(s) : Salmonella Typhi Immunotherapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Lausanne University Hospital

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Prokarium

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vesibax

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Korea Investment Partners

                            Deal Size : $21.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Prokarium Closes $21M Series B Financing Round and Strengthens Board

                            Details : Financing will support the clinical development of Prokarium’s microbial immunotherapy for non-muscle invasive bladder cancer as well as expansion of pipeline across multiple solid tumours.

                            Brand Name : Vesibax

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 27, 2020

                            Lead Product(s) : Vesibax

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Korea Investment Partners

                            Deal Size : $21.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth